Literature DB >> 18981243

Toll-like receptor prestimulation increases phagocytosis of Escherichia coli DH5alpha and Escherichia coli K1 strains by murine microglial cells.

Sandra Ribes1, Sandra Ebert, Dirk Czesnik, Tommy Regen, Andre Zeug, Stephanie Bukowski, Alexander Mildner, Helmut Eiffert, Uwe-Karsten Hanisch, Sven Hammerschmidt, Roland Nau.   

Abstract

Meningitis and meningoencephalitis caused by Escherichia coli are associated with high rates of mortality. When an infection occurs, Toll-like receptors (TLRs) expressed by microglial cells can recognize pathogen-associated molecular patterns and activate multiple steps in the inflammatory response that coordinate the brain's local defense, such as phagocytosis of invading pathogens. An upregulation of the phagocytic ability of reactive microglia could improve the host defense in immunocompromised patients against pathogens such as E. coli. Here, murine microglial cultures were stimulated with the TLR agonists Pam(3)CSK(4) (TLR1/TLR2), lipopolysaccharide (TLR4), and CpG oligodeoxynucleotide (TLR9) for 24 h. Upon stimulation, levels of tumor necrosis factor alpha and the neutrophil chemoattractant CXCL1 were increased, indicating microglial activation. Phagocytic activity was studied after adding either E. coli DH5alpha or E. coli K1 strains. After 60 and 90 min of bacterial exposure, the number of ingested bacteria was significantly higher in cells prestimulated with TLR agonists than in unstimulated controls (P < 0.01). Addition of cytochalasin D, an inhibitor of actin polymerization, blocked >90% of phagocytosis. We also analyzed the ability of microglia to kill the ingested E. coli strains. Intracellularly surviving bacteria were quantified at different time points (90, 150, 240, and 360 min) after 90 min of phagocytosis. The number of bacteria killed intracellularly after 6 h was higher in cells primed with the different TLR agonists than in unstimulated microglia. Our data suggest that microglial stimulation by the TLR system can increase bacterial phagocytosis and killing. This approach could improve central nervous system resistance to infections in immunocompromised patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981243      PMCID: PMC2612236          DOI: 10.1128/IAI.00903-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Rapidly maturing red fluorescent protein variants with strongly enhanced brightness in bacteria.

Authors:  Meike Sörensen; Christoph Lippuner; Toralf Kaiser; Ana Misslitz; Toni Aebischer; Dirk Bumann
Journal:  FEBS Lett       Date:  2003-09-25       Impact factor: 4.124

3.  Different Toll-like receptor agonists induce distinct macrophage responses.

Authors:  B W Jones; T K Means; K A Heldwein; M A Keen; P J Hill; J T Belisle; M J Fenton
Journal:  J Leukoc Biol       Date:  2001-06       Impact factor: 4.962

4.  Interaction of lipoteichoic acid and CpG-DNA during activation of innate immune cells.

Authors:  Alexander H Dalpke; Markus Frey; Siegfried Morath; Thomas Hartung; Klaus Heeg
Journal:  Immunobiology       Date:  2002-10       Impact factor: 3.144

5.  Extraintestinal pathogenic Escherichia coli survives within neutrophils.

Authors:  Helen Nazareth; Stacy A Genagon; Thomas A Russo
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

6.  Streptococcus suis and group B Streptococcus differ in their interactions with murine macrophages.

Authors:  M A Segura; P Cléroux; M Gottschalk
Journal:  FEMS Immunol Med Microbiol       Date:  1998-07

7.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

8.  Upregulation and induction of surface antigens with special reference to MHC class II expression in microglia in postnatal rat brain following intravenous or intraperitoneal injections of lipopolysaccharide.

Authors:  J Xu; E A Ling
Journal:  J Anat       Date:  1994-04       Impact factor: 2.610

Review 9.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

10.  Microglia activation in sepsis: a case-control study.

Authors:  Afina W Lemstra; Jacqueline C M Groen in't Woud; Jeroen J M Hoozemans; Elise S van Haastert; Annemiek J M Rozemuller; Piet Eikelenboom; Willem A van Gool
Journal:  J Neuroinflammation       Date:  2007-01-15       Impact factor: 8.322

View more
  33 in total

1.  Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis.

Authors:  Peter J Wermuth; Sergio A Jimenez
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

2.  Vitamin d deficiency reduces the immune response, phagocytosis rate, and intracellular killing rate of microglial cells.

Authors:  Marija Djukic; Marie Luise Onken; Sandra Schütze; Sandra Redlich; Alexander Götz; Uwe-Karsten Hanisch; Thomas Bertsch; Sandra Ribes; Andrea Hanenberg; Simon Schneider; Cornelius Bollheimer; Cornel Sieber; Roland Nau
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

3.  Self-Assembly of a Multifunctional Lipid With Core-Shell Dendrimer DNA Nanoparticles Enhanced Efficient Gene Delivery at Low Charge Ratios into RPE Cells.

Authors:  Da Sun; Hiroshi Maeno; Maneesh Gujrati; Rebecca Schur; Akiko Maeda; Tadao Maeda; Krzysztof Palczewski; Zheng-Rong Lu
Journal:  Macromol Biosci       Date:  2015-08-13       Impact factor: 4.979

Review 4.  The multifaceted profile of activated microglia.

Authors:  Marina A Lynch
Journal:  Mol Neurobiol       Date:  2009-07-23       Impact factor: 5.590

5.  Suppressed microglial E prostanoid receptor 1 signaling selectively reduces tumor necrosis factor alpha and interleukin 6 secretion from toll-like receptor 3 activation.

Authors:  Xianwu Li; Eiron Cudaback; C Dirk Keene; Richard M Breyer; Thomas J Montine
Journal:  Glia       Date:  2011-01-06       Impact factor: 7.452

Review 6.  Microglia and inflammation in Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; Gary E Landreth
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

7.  Toll-like receptor 2 ligand pretreatment attenuates retinal microglial inflammatory response but enhances phagocytic activity toward Staphylococcus aureus.

Authors:  Travis Kochan; Anuj Singla; Joaquin Tosi; Ashok Kumar
Journal:  Infect Immun       Date:  2012-03-19       Impact factor: 3.441

8.  CpG-ODN-mediated TLR9 innate immune signalling and calcium dyshomeostasis converge on the NFκB inhibitory protein IκBβ to drive IL1α and IL1β expression.

Authors:  Robyn De Dios; Leanna Nguyen; Sankar Ghosh; Sarah McKenna; Clyde J Wright
Journal:  Immunology       Date:  2020-03-18       Impact factor: 7.397

9.  Toll-like receptor stimulation enhances phagocytosis and intracellular killing of nonencapsulated and encapsulated Streptococcus pneumoniae by murine microglia.

Authors:  Sandra Ribes; Sandra Ebert; Tommy Regen; Amit Agarwal; Simone C Tauber; Dirk Czesnik; Annette Spreer; Stephanie Bunkowski; Helmut Eiffert; Uwe-Karsten Hanisch; Sven Hammerschmidt; Roland Nau
Journal:  Infect Immun       Date:  2009-11-23       Impact factor: 3.441

10.  Resistance of the brain to Escherichia coli K1 infection depends on MyD88 signaling and the contribution of neutrophils and monocytes.

Authors:  Sandra Ribes; Tommy Regen; Tanja Meister; Simone C Tauber; Sandra Schütze; Alexander Mildner; Matthias Mack; Uwe-Karsten Hanisch; Roland Nau
Journal:  Infect Immun       Date:  2013-03-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.